FR2622192B1 - - Google Patents

Info

Publication number
FR2622192B1
FR2622192B1 FR8813812A FR8813812A FR2622192B1 FR 2622192 B1 FR2622192 B1 FR 2622192B1 FR 8813812 A FR8813812 A FR 8813812A FR 8813812 A FR8813812 A FR 8813812A FR 2622192 B1 FR2622192 B1 FR 2622192B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR8813812A
Other languages
French (fr)
Other versions
FR2622192A1 (fr
Inventor
Edgar E Ribi
Kent R Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FR2622192A1 publication Critical patent/FR2622192A1/fr
Application granted granted Critical
Publication of FR2622192B1 publication Critical patent/FR2622192B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
FR8813812A 1987-10-22 1988-10-21 Derives de lipide monophosphoryle a et leur procede de preparation Granted FR2622192A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/112,742 US4987237A (en) 1983-08-26 1987-10-22 Derivatives of monophosphoryl lipid A

Publications (2)

Publication Number Publication Date
FR2622192A1 FR2622192A1 (fr) 1989-04-28
FR2622192B1 true FR2622192B1 (esLanguage) 1994-11-10

Family

ID=22345625

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8813812A Granted FR2622192A1 (fr) 1987-10-22 1988-10-21 Derives de lipide monophosphoryle a et leur procede de preparation

Country Status (10)

Country Link
US (1) US4987237A (esLanguage)
JP (1) JPH075623B2 (esLanguage)
BE (1) BE1003250A5 (esLanguage)
CA (1) CA1308711C (esLanguage)
CH (1) CH676715A5 (esLanguage)
DE (1) DE3836006C2 (esLanguage)
FR (1) FR2622192A1 (esLanguage)
GB (1) GB2211502B (esLanguage)
IT (1) IT1230592B (esLanguage)
NL (1) NL8802595A (esLanguage)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
US5498708A (en) * 1989-07-18 1996-03-12 Montefiore Medical Center Method of synthesizing polyesters
EP0482206A4 (en) * 1990-04-12 1992-08-19 Japan Tobacco Inc. 4,6-o-hydroxyphosphorylglucosamine derivative
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5164375A (en) * 1991-09-27 1992-11-17 Merck & Company, Inc. Antifungal agent
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001269695B2 (en) 2000-05-19 2007-02-15 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
US20030139356A1 (en) 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
CN1301134C (zh) * 2002-02-04 2007-02-21 科里克萨有限公司 新的免疫效应化合物
AU2003213640A1 (en) * 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
KR20050037460A (ko) 2002-07-08 2005-04-21 코릭사 코포레이션 아미노알킬 글루코사미나이드 포스페이트 및 이당류이뮤노이펙터의 제조 방법, 및 이를 위한 중간체
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
ATE324903T1 (de) * 2003-02-18 2006-06-15 Clinique La Prairie Res Sa Zusammensetzungen enthaltend fötales hämoglobin und bakterielles endotoxin und fakultativ zusätzliche fötale leberkomponenten
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2539818T3 (es) * 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
WO2009073179A2 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US10166279B2 (en) 2013-02-20 2019-01-01 Bergen Teknologioverføring Vaccine
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
KR20200051778A (ko) 2017-09-13 2020-05-13 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
US20190275135A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against intra-abdominal infections
US12527853B2 (en) 2018-08-24 2026-01-20 Vestlandets Innovasjonsselskap As (Vis) Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
AU2021208493B2 (en) 2020-01-16 2023-03-30 Janssen Pharmaceuticals, Inc. FimH mutant, compositions therewith and use thereof
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
EP4313135A1 (en) 2021-04-01 2024-02-07 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0414725Y2 (esLanguage) * 1980-09-30 1992-04-02
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS62129293A (ja) * 1985-11-28 1987-06-11 Toho Yakuhin Kogyo Kk 親水性のリピドａ単糖類縁体
JPS62195396A (ja) * 1986-02-20 1987-08-28 Toho Yakuhin Kogyo Kk 親水性及び疎水性の基を置換したりピドａ単糖類縁体

Also Published As

Publication number Publication date
CA1308711C (en) 1992-10-13
BE1003250A5 (fr) 1992-02-11
JPH075623B2 (ja) 1995-01-25
JPH075623B1 (esLanguage) 1995-01-25
IT8822399A0 (it) 1988-10-21
DE3836006A1 (de) 1989-05-03
JPH01146891A (ja) 1989-06-08
NL8802595A (nl) 1989-05-16
GB8824330D0 (en) 1988-11-23
US4987237A (en) 1991-01-22
DE3836006C2 (de) 1996-07-11
FR2622192A1 (fr) 1989-04-28
GB2211502B (en) 1992-02-19
IT1230592B (it) 1991-10-28
CH676715A5 (esLanguage) 1991-02-28
GB2211502A (en) 1989-07-05

Similar Documents

Publication Publication Date Title
FR2622192B1 (esLanguage)
GR3005626T3 (esLanguage)
GR3003689T3 (esLanguage)
GR3003922T3 (esLanguage)
IN170600B (esLanguage)
AU632031B2 (esLanguage)
IN166808B (esLanguage)
AU6557686A (esLanguage)
IN171237B (esLanguage)
IN170836B (esLanguage)
AU7458787A (esLanguage)
IN167604B (esLanguage)
IN171502B (esLanguage)
AU6655286A (esLanguage)
AU7493687A (esLanguage)
AU7016787A (esLanguage)
AU6922687A (esLanguage)
AU5926286A (esLanguage)
AU6799487A (esLanguage)
AU6246086A (esLanguage)
AU7799887A (esLanguage)
AU7042087A (esLanguage)
AU6702486A (esLanguage)
BG45123A1 (esLanguage)
BG44957A1 (esLanguage)